Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-06-17 / J Clin Oncol 29: 2011 (suppl; abstr e13029)Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr e13084)Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-03-01 / Scand. J. Immunol. 2011 Mar;73(3):222-33Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-02-10 / Gene Ther. 2011 Jun;18(6):584-93New approaches to the development of adenoviral dendritic cell vaccines in melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-12-01 / Curr Opin Investig Drugs 2010 Dec;11(12):1399-408Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-60Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-10-20 / Cancer Immunol. Immunother. 2011 Jan;60(1):123-31Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-10-01 / Cytotherapy 2010 Oct;12(6):721-34Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-09-27 / J Transl Med 2010 Sep;8:89
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution